Teicoplanin combined with conventional vancomycin therapy for the treatment of pulmonary methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis infections

Table 1 Average symptom relief time for patients treated with either vancomycin only or vancomycin and teicoplanin (mean ± SD)

	Vancomycin only	Vancomycin + teicoplanin	P value
Patients (n)	43	43
Cough and expectoration resolution (d)	8.29 ± 2.15	6.12 ± 1.56	0.000
WBC normalization (d)	8.68 ± 2.44	6.77 ± 2.13	0.000
Body temperature normalization (d)	5.68 ± 1.18	4.07 ± 1.09	0.000
Rales resolution (d)	8.89 ± 2.02	6.64 ± 1.43	0.000

WBC: White blood cell count.

Table 2 Treatment effects for patients treated with vancomycin (only) or vancomycin and teicoplanin, n (%)

Group	Number of cases	Markedly effective	Effective	Ineffective	Total efficiency
Study group	43	26 (60.47)	14 (32.56)	3 (6.98)	40 (93.02)
Control group	43	18 (41.86)	15 (34.88)	10 (23.26)	33 (76.74)
χ2 value					4.441
P value					0.035

Table 3 Inflammation marker levels in patients treated with vancomycin (only) or vancomycin and teicoplanin

Group	Number of cases	PCT (ng/mL)	IL-1β (pg/mL)	TNF-α (pg/mL)	CRP (mg/L)	CPIS (point)
Before treatment
Study group	43	0.86 ± 0.23	223.37 ± 36.25	139.74 ± 23.65	91.39 ± 10.68	7.69 ± 2.88
Control group	43	0.91 ± 0.20	219.29 ± 35.56	142.91 ± 20.88	89.24 ± 12.29	8.01 ± 3.04
t value		1.076	0.527	0.659	0.866	0.501
P value		0.285	0.600	0.512	0.389	0.618
After treatment
Study group	43	0.28 ± 0.03	141.18 ± 18.62	41.46 ± 9.08	11.76 ± 4.43	2.19 ± 0.79
Control group	43	0.34 ± 0.05	163.53 ± 23.84	50.96 ± 10.35	18.25 ± 5.39	3.87 ± 1.01
t value		6.748	4.845	4.525	6.100	8.591
P value		0.000	0.000	0.000	0.000	0.000

CPIS: Clinical pulmonary infection score; CRP: C-reactive protein; IL -1β: Interleukin-1β; PCT: Procalcitonin; TNF-α: Tumor necrosis factor-α.

Table 4 Adverse events experienced by patients treated with vancomycin (only) or with vancomycin and teicoplanin, n (%)

Group	Number of cases	Gastrointestinal reaction	Dizziness and headache	Vomiting and nausea	Total incidence
Study group	43	2 (4.65)	1 (2.33)	2 (4.65)	5 (11.63)
Control group	43	0 (0.00)	2 (4.65)	1 (2.33)	3 (6.98)
χ2 value					0.551
P value					0.458